Healthcare Global Enterprises Ltd

- Healthcare Global Enterprises Limited is considering a primary equity infusion with the incoming new investor KKR expected to replace CVC. - The primary equity infusion is aimed partly at reducing debt, thereby lowering interest costs and improving PAT. - No specific amount or timeline has been disclosed yet; the decision will be made in the coming few months. - Current year's capex is about INR 280 crores, mostly funded from internal accruals, with no concrete plans for further growth capex beyond this. - Ashutosh Kumar mentioned that depending on the quantum of primary equity infusion and its allocation towards debt reduction, it would help reduce interest cost and improve profitability. - The company will keep the market appraised of growth plans and associated incremental capex at an appropriate time.

- FY '26 Capex planned at approximately INR 286 crores focused on network expansion and technology upgrades, including existing centers in Bangalore and Cuttack. - Addition of over 900 beds across the network within the next 3 years, including 350 beds fully invested but not yet operational. - Investment in advanced technologies such as linear accelerator (LINAC) machines, PET-CT scanners, and robotic surgery platforms to enhance precision cancer care. - Two new hospitals to commence operations in Bangalore in FY '26: one in North Bangalore (second half of FY '26) and another in Whitefield as an extension of the flagship center. - Acquisition of MG Hospital in Vizag and inauguration of a new flagship 189-bedded cancer center in Ahmedabad in FY '26. - Strategic focus on early cancer detection and precision medicine capabilities with investments in cutting-edge diagnostic equipment like the Orbitrap Astral Mass Spectrometer.

- FY '25 revenue grew 16% to INR 2,223 crores; Q4 revenue rose 18% YoY to INR 585 crores. - Excluding Milann, core HCG centers saw 17% revenue growth and 17% EBITDA growth in FY '25. - Outpatient footfall increased by 13.8%; chemotherapy sessions grew 24%, indicating higher patient demand. - Emerging centers delivered 32% revenue growth with improving EBITDA margins, expected to boost overall margins. - Digital revenue doubled in FY '25; with efforts to scale digital channels further expected to contribute significantly to top-line growth. - New facilities: flagship 189-bed center in Ahmedabad operationalized; two new hospitals in Bangalore to come online in FY '26 to tap new markets and enhance capacity. - Plans to operationalize over 900 beds across the network within 3 years including 350 beds invested but not yet operational. - ARPOB expected to grow 7-8% in FY '26 fueled by high-end treatment modalities and decreased hospital stay. - Expectation of moving from consolidation to a high-growth phase with incoming new investors supporting expansion.

- HCG expects continued strong revenue and EBITDA growth in FY '26, building on a 16-18% revenue growth in FY '25 and a 44% EBITDA increase in emerging centers. - ARPOB (Average Revenue Per Occupied Bed) growth of 7-8% is anticipated for FY '26 due to shorter hospital stays and advanced treatments. - Expansion includes operationalizing 900+ beds over three years, including 350 already invested but not yet operational. - Emerging centers and new facilities like Ahmedabad and Bangalore are expected to drive higher ARPOB and margins, aiming for stable EBITDA margins in the low 20% range in the near future. - PAT is expected to normalize and improve as EBITDA scales, offsetting higher depreciation and interest costs from recent expansions and acquisitions. - Digital revenue streams are growing rapidly, doubling over the past year, expected to contribute increasingly to top-line growth. - Management is considering primary equity infusion to reduce debt and fund growth, supporting sustainable profit improvements.

The transcript does not provide explicit details on the current or expected order book or pending orders for Healthcare Global Enterprises Limited. However, some relevant points related to capacity expansion and investments include: - Plans to operationalize over 900 beds across their network within the next 3 years, including 350 beds already fully invested but not yet operational (Page 6). - Growth capex guidance of approximately INR 280-286 crores in FY '26, aligned with network expansion and technology upgrades (Pages 6 and 10). - New centers in Bangalore, Ahmedabad, Mumbai, and Kolkata expected to drive growth with higher ARPOB (Page 10). - Primary equity infusion anticipated to support debt reduction and fund growth; specifics pending based on new investor involvement (Pages 6 and 9). No direct mention of order book or pending orders is available in the provided transcript.